ImmuPharma plc
LSE:IMM

Jigglypop Analysis For ImmuPharma plc 🤓

ImmuPharma (GBp 7.16) sits well below its 52-week high of 19.4 yet far above the 1.386 trough, underscoring a wide risk band. With the 200-day MA (5.55) below spot and the 50-day (7.47) just above, trend momentum is constructive, but the share still trades at ~37% of its peak and ~5x the low—classic speculative territory. The story hinges on P140 Phase III and a prospective partnership now guided to 2026; cash runway into H2 2026 tempers dilution risk, while patent steps and a companion diagnostic add optionality. Near-term price pops (+15% month, +3.6% day) reflect deal hopes rather than fundamentals. Verdict: speculative biotech with binary catalysts, suitable for risk-tolerant investors, not a traditional value play. Expect volatility to remain elevated.

About ImmuPharma plc 👋

ImmuPharma plc is a biopharmaceutical company that discovers and develops peptide-based medicines in the United Kingdom. Its peptide-based programs concentrate on autoimmunity and inflammation, as well as anti-infective therapeutic areas. The company’s lead product candidate is P140, a peptide technology platform, which is in a Phase III clinical trial targeting autoimmune disease in systemic lupus erythematosus; P140, which is in a Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of the peripheral nerves; and P140 that also addresses other indications including acute and chronic asthma, gout, irritable bowel disease, and periodontitis. Its pre-clinical products include BioAMB, a peptide-based Amphotericin-B formulation for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin-based therapy for anti-infection. It has a collaboration with Centre National de la Recherche Scientifique for the development of the 1P40 platform; and a license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.